The purpose of this study is to further evaluate the long-term safety and tolerability of daily dosing of rimegepant for the prevention of episodic migraine.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants With On-Treatment Adverse Events (AEs) (Frequency >=5%) According to Intensity
Timeframe: From start of study treatment (Day 1) up to 7 days after the last dose of study treatment (Up to 25 weeks)
Number of Participants With On-Treatment Serious Adverse Events (SAEs)
Timeframe: From start of study treatment (Day 1) up to 7 days after the last dose of study treatment (Up to 25 weeks)
Number of Participants With AEs Leading to Study Drug Discontinuation
Timeframe: From start of study treatment (Day 1) up to 7 days after the last dose of study treatment (Up to 25 weeks)
Number of Participants With Grade 3 to 4 Laboratory Abnormalities On-Treatment Using Common Technical Criteria for Adverse Events- Division of Acquired Immune Deficiency Syndrome (CTCAE/DAIDS) Toxicity Grading Scale
Timeframe: From start of study treatment (Day 1) up to 7 days after the last dose of study treatment (Up to 25 weeks)
Number of Participants With Grade 3 to 4 Laboratory Abnormalities On-Treatment Using Food and Drug Administration (FDA) Toxicity Grading Scale
Timeframe: From start of study treatment (Day 1) up to 7 days after the last dose of study treatment (Up to 25 weeks)